Synthetic Biologics (SYN) Reports FY 21 EPS of ($0.19)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Synthetic Biologics Reports 2021 Year End Operational Highlights and Financial Results
March 16, 2022 4:05 PM EDT-Completed acquisition of VCN Biosciences, expanding pipeline into oncology-
-VCN-01 received Orphan Drug Designation for retinoblastoma from the U.S. FDA-
-As of December 31, 2021, Synthetic Biologics reports $67.3 million in cash, which is expected to provide runway through the end of 2023-
-Conference call and webcast to be held today at 4:30 p.m. ET-
ROCKVILLE, Md., March 16, 2022 (GLOBE NEWSWIRE) --... More
